Advanced therapy medicinal product (ATMP) companies are ushering in a new frontier of medicine and technologies poised to revolutionize human health, but are ATMP facilities keeping up? The industry is advancing at such a rapid pace that these companies are faced with vast new complexities when developing and manufacturing their products.
Too often, the term “closed process” is thrown around without an understanding of the salient issues. Pharmaceutical process closure can certainly provide many benefits, but there are various impacts and requirements depending on the ultimate goal and the specific process you are trying to close.
Learn how the application of best practice design principles can help mitigate the risks confronting biotechnology companies when navigating the uncertainty surrounding the demand profile of the product pipeline.
In the past 5 years, the biopharmaceutical industry has seen unprecedented change. Precipitated by the need to support a global client base with products that are more targeted, efficacious and cost-effective, the challenge to have a robust manufacturing supply chain is more crucial than ever to a company’s survival.